factorxa

Abelacimab (MAA868), a fully human IgG1 monoclonal antibody that binds to and blocks the activation of FXI, is an anticoagulant used in the study of thromboembolic diseases.

Garadacimab (CSL312) is a potent whole-human IgG4 monoclonal antibody targeting activation factor XII (FXIIa). Garadacimab can be used to study hereditary angioedema.

Denecimig (Mim8) is a bispecific and humanized IgG4κ antibody mimicking activated coagulation factor VIII with anti-FIXa and anti-FX arms, which is used for the treatment of hemophilia A and coagulation disorders primarily by facilitating the assembly of activated coagulation factors IXa (FIXa) and X (FX) on platelet membranes, stimulating activation of FX, and arresting bleeding.

Lofacimig is a bispecific antibody of VH-VH-G1(h-CH2-CH3) dimer type that targets FXI/PTA.

Amrecibart is a human-derived IgG4κ monoclonal antibody that acts as an anticoagulant factor 11 (XI) inhibitor.

Zemocimig is a human-derived IgG4κ monoclonal antibody that functions as an anticoagulant targeting factor F9.